Novel chemoembolization using calcium-phosphate ceramic microsphere incorporating TNP-470, an anti-angiogenic agent

Cancer Science

Volumn 101, Issue 4, 2010, Pages 984-990

  Emoto, Makoto ^a   Naganuma, Yasuko ^a   Choijamts, Batsuren ^a   Ohno, Toshiki ^b   Yoshihisa, Hajime ^b   Kanomata, Nobuhiko ^c   Kawarabayashi, Tatsuhiko ^a   Aizawa, Mamoru ^b  

^a FUKUOKA UNIVERSITY   (Japan)

^b MEIJI UNIVERSITY   (Japan)

^c WASEDA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM PHOSPHATE CERAMIC; CD31 ANTIGEN; FUMAGILLOL CHLOROACETYLCARBAMATE; MICROSPHERE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CALCIUM PHOSPHATE; CYCLOHEXANE DERIVATIVE; O-(CHLOROACETYLCARBAMOYL)FUMAGILLOL; SESQUITERPENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CHEMOEMBOLIZATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION; UTERUS SARCOMA; ANIMAL; CERAMICS; DRUG SCREENING; EVALUATION; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; UTERUS CANCER; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CALCIUM PHOSPHATES; CELL LINE, TUMOR; CERAMICS; CYCLOHEXANES; FEMALE; HUMANS; MICE; MICE, NUDE; MICROSPHERES; SESQUITERPENES; UTERINE NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77957263360     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01479.x     Document Type: Article

References (36)

1. Salazar OM, Bonfiglio TA, Patten SF et al. Uterine sarcomas: Natural history, treatment and prognosis. Cancer 1978; 42: 1152-60.
2. Spanos WJ Jr, Wharton JT, Gomez L, Fletcher GH, Oswald MJ. Malignant mixed Müllerian tumors of the uterus. Cancer 1984; 15: 53. Review.
3. Acharya S, Hensley ML, Montag AC, Flemming GF. Rate uterine cancers. Review. Lancet Oncol 2005; 6: 961-71.
4. Rose PG, Piver MS, Tsukada Y, Lau T. Patterns of metastasis in uterine sarcoma. An autopsy study. Cancer 1989; 63: 935-8.
5. Emoto M, Iwasaki H, Ishiguro M et al. Angiogenesis in carcinosarcomas of the uterus: Differences in the microvessel density and expression of vascular endothelial growth factor between the epithelial and mesenchymal elements. Hum Pathol 1999; 30: 1232-41.
6. Emoto M, Charnock-Jones DS, Licence D et al. Localisation of the VEGF and angiopoietin genes in uterine carcinosarcoma. Gynecol Oncol 2004; 95: 474-82.
7. Kawashita M, Shineha R, Kim HM et al. Preparation of ceramic microspheres for in situ radiotherapy of deep-seated cancers. Biomaterials 2003; 24: 2955-63.
8. Petersen LK, Narashimhan B. Combinational design of biomaterials for drug delivery: opportunities and challenges. Expert Opin Drug Deliv 2008; 5: 837-46.
9. Yuan H, Kurashina K, de Bruijn JD, Li Y, de Groot K, Zhang X. A preliminary study on osteoinduction of two kinds of calcium-phosphate ceramics. Biomaterials 1999; 20: 1799-806.
10. Nagayama M, Takeuchi H, Doi Y. Comparison of carbonate apatite and b-tricalcium phosphate (resorbable calcium phosphates) implanted subcutaneously into the back of rats. Dent Mater J 2006; 25: 219-25.
11. Victor SP, Sampath Kumar TS. BCP ceramics microspheres as drug delivery carriers: synthesis, characterization, and doxycycline release. J Mater Sci Mater Med 2008; 19: 283-90.
12. Kawata M, Uchida H, Itatani K, Okada I, Koda S, Aizawa M. Development of porous ceramics with well-controlled porosities and pore sizes from apatite fibers and their evaluations. J Mater Sci Mater Med 2004; 15: 817-23.
13. Aizawa M, Porter AE, Best SM, Bonfield M. Ultrastructural observation of single-crystal apatite fibres. Biomaterials 2005; 26: 3427-33.
14. Morisue H, Matsumoto M, Chiba K et al. Novel apatite fiber scaffolds can promote three-dimensional proliferation of osteoblasts in rodent bone regeneration models. J Biomed Mater Res A. 2009; 90: 811-8.
15. Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-7.
16. Roodhart JM, Langenberg MH, Witteveen E, Voest EE. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 2008; 3: 132-43. Review.
17. Miura S, Emoto M, Matsuo Y, Kawarabayashi T, Saku K. Carcinosarcoma-induced endothelial cells tube formation through KDR/Flk-1 is blocked by TNP-470. Cancer Lett 2004; 203: 45-50.
18. Emoto M, Ishiguro M, Iwasaki H, Kikuchi M, Kawarabayashi T. Effect of Angiogenesis Inhibitor TNP-470 on the Growth, Blood Flow, and Microvessel Density in Xenografts of Human Uterine Carcinosarcoma in Nude Mice. Gynecol Oncol 2003; 89: 88-94.
19. Emoto M, Tachibana K, Iwasaki H, Kawarabayashi T. Antitumor effect of TNP-470, an angiogenesis inhibitor, combined with ultrasound irradiation for human uterine sarcoma xenografts evaluated using contrast color Doppler ultrasound. Cancer Sci 2007; 98: 929-35.
20. Ingber D, Fujita T, Kishimoto S et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348: 555-7.
21. Zhang Y, Griffith EC, Sage J, Jacks T, Liu JO. Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc Natl Acad Sci U S A 2000; 97: 6427-32.
22. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci U S A 1997; 94: 6099-103.
23. Yanase T, Tamura M, Fujita K, Kodama S, Tanaka K. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 1993; 53: 2566-70.
24. Yoshida T, Kaneko Y, Tsukamoto A, Han K, Ichinose M, Kimura S. Suppression of hepatoma growth and angiogenesis by a fumagillin derivative TNP 470. Cancer Res 1998; 58: 3751-6.
25. Inoue K, Chikazawa M, Fukata S, Yoshikawa C, Shuin T. Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastatic human transitional cell carcinoma in the urinary bladder. Clin Cancer Res 2002; 8: 2389-98.
26. Inoue K, Chikazawa M, Fukata S, Yoshikawa C, Shuin T. Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma. Clin Cancer Res 2003; 9: 886-99.
27. Nahari D, Satchi-Fainaro R, Chen M et al. Tumor cytotoxicity and endothelial Rac inhibition induced by TNP-470 in anaplastic thyroid cancer. Mol Cancer Ther 2007; 6: 1329-37.
28. Emoto M, Iwasaki H, Oshima K, Kikuchi M, Kaneko Y, Kawarabayashi T. Characteristics of rhabdomyosarcoma cell lines derived from uterine carcinosarcomas. Virchow Archiv 1997; 431: 249-56.
29. Aizawa M, Hanazawa T, Itatani K, Howell FS, Kishioka A. Characterization of hydroxyapatite powders prepared by ultrasonic spray-pyrolysis technique. J Mater Sci 1999; 34: 2865-73.
30. Ohno T, Aizawa M. Effect of the concentrations of the starling solution on the syntheses and powder properties of hollow tricalcium-phosphate microspheres by ultrasonic spray-pyrolysis. Key Engineer Mater 2006; 309: 235-8.
31. Yasukawa T, Kimura H, Tabata Y et al. Targeted delivery of anti-angiogenic agent TNP-470 using water-soluble polymer in the treatment of choroidal neovascularization. Invest Ophthalmol Vis Sci 1999; 40: 2690-6.
32. Satchi-Fainaro R, Puder M, Davies JW et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med 2004; 10: 255-61.
33. Matsumura Y. Poly (amino acid) micelle nanocarriers in preclinical and clinical studies (Review). Adv Drug Deliv Rev 2008; 22: 60.
34. Kubo M, Kuwayama N, Hirashima Y, Takaku A, Ogawa T, Endo S. Hydroxyapatite ceramics as a particulate embolic material: report of the physical properties of the hydroxyapatite particles and the animal study. AJNR 2003; 24: 1540-4.
35. Kubo M, Kuwayama N, Hirashima Y, Takaku A, Ogawa T, Endo S. Hydroxyapatite ceramics as a particulate embolic material: report of the clinical experience. AJNR 2003; 24: 1545-7.
36. Sergio A, Cristofori C, Cardin R et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastro 2008; 103: 914-21.